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Accepted 4 August 2015The survival of multiple myeloma (MM) patients signiﬁ-
cantly increased in the last decades because of the intro-
duction of novel agents (immunomodulatory agents [IMIDs]
and proteasome inhibitors). This improvement was also
recently seen in patients older than 65 years of age. This was
probably related to better supportive measures that trans-
lated into a decrease in early mortality rate [1]. Patients older
than 65 years of age are generally considered ineligible for
high-dose chemotherapy and autologous stem cell trans-
plantation (ASCT), especially in Europe. For younger patients,
ASCT is currently the standard of care. ASCT improved overall
survival (OS) compared with chemotherapy [2-4], and
recently it showed to be superior to chemotherapy plus
IMIDs [5]. In the United States, Medicare covers the costs
associated with ASCT for patients up to 78 years of age, with
a consequent rise in the utilization of ASCT in the elderly
population. Results on the efﬁcacy of ASCT in patients older
than 65 are not unequivocal. There is only 1 trial that
compared reduced-intensity ASCT to chemotherapy plus
IMIDs. The trial showed improved OS for patients random-
ized to chemotherapy plus IMIDs [6]; however, patients
randomized to ASCT did not receive any novel agent upfront,
and this could have, at least in part, biased the results. Results
of a phase II trial evaluating novel agents plus reduced-
intensity ASCT in the elderly suggested a greater efﬁcacy of
ASCT, even in this population [7]. A recent retrospective
analysis including patients treated in the last 15 years
showed an OS advantage, including in patients older than 65
years who received ASCT, in comparison with patients who
did not [1]. With all the limitations, there are still signs of
improvement with ASCT in elderly patients.
The increased utilization of novel agents inMM treatment
added the cost of therapy over time [8], as did the adminis-
tration of high-dose therapy and transplantation [9]. The
cost of treatments raises reasonable concerns. Health care
systems aim to maximize the outcome while working within
a tight budget. Thus, when selecting therapy, physicians
should take into account not only the efﬁcacy but also the
cost effectiveness of different treatment options.
In this issue of Biology of Blood and Marrow Trans-
plantation, Shah et al. evaluated the cost effectiveness of
ASCT in patients over the age of 65 using a large data set of US
national data [10]. They included 270 patients who
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First, the population of patients included represents a good
sample of elderly patients eligible for ASCT: the median age
was 68 years (with fewer than 10% of patients older than 75
years) and two thirds of them had no comorbidities. Second,
in this population of patients, the median OS in patients who
underwent ASCT was 58 months, signiﬁcantly longer than
that reported in patients who did not (37 months), thus
suggesting that elderly subjects who are ﬁt and able to un-
dergo ASCT beneﬁt from this treatment. Third, the authors
calculated an average incremental cost-effectiveness ratio of
less than $100,000 per life-year gained ($72,852 per life-year
gained) and showed that ASCT in eligible patients older than
65 year is cost effective 90% of the time.
The current article strengthens the idea that ASCT in eligible
patients older than 65 years is an effective option. Patients un-
dergoing ASCT lived approximately 1.37 years longer than pa-
tients who received a different treatment. The survival rate
reported is comparable to previously published studies
enrolling younger patients [2-4]. Nevertheless, recent studies of
ASCT in patients up to 65 years of age do report longer survival
times [5], but this difference could partly be explained by the
wider access to novel agents in more recent years (the time
frame analyzed in this study was 2000 to 2007). The authors
evaluated a large set of “real world” national data, providing
results coming from the real-life context that conﬁrm the
promising results coming from clinical trials in this setting. This
is, of course, a keyconsideration, even if this analysisneeds tobe
re-evaluated outside the United States, given the different
availability and cost of drugs worldwide. In the present study,
theauthors selectedpatientswhoreceivedASCT, thusexcluding
from the analysis those patients who were considered eligible
for ASCT at diagnosis, but who did not receive it for early pro-
gressionor for toxicityexperiencedduring induction. This could
bea limitationof the study, related to its retrospectivenature.Of
note, it is necessary to understand that these results do
not apply to all elderly patients, butonly to those eligible for the
procedure. Patients undergoing ASCT in theMedicare database
had amedian age of 68 years (two thirds of themyounger than
70years), andmostof themhadnocomorbidities.Other reports
showed that induction treatments and ASCT in the elderly
population are more feasible in patients younger than 70 years
[7]. Fit patients with no comorbidities can tolerate the proce-
dure better, with fewer adverse events and a better safety/efﬁ-
cacy proﬁle. Fewer adverse events translate into a better quality
of life and lowercosts. The correct identiﬁcationof patientswho
may beneﬁt from a speciﬁc treatment is the ﬁrst step to maxi-
mize the cost-effectiveness ratio associatedwith therapy. In the
subset of elderly patients eligible for ASCT (the authors appro-
priately matched patients according to several variables,
includingageandcomorbidities), ASCTwas cost effective90%of
the time.
A second limitation of the present analysis is that the cost
of oral drugs (IMIDs) was not included. In present years, the
use and the availability of novel agents have considerably
increased. Several combinations, including second- and
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hibitors, are currently under investigation in newly diag-
nosed and relapsed settings, and these agents are used both
in strategies that incorporate ASCT or do not. In terms of
efﬁcacy, a number of combinations can challenge the role of
ASCT. A recent review suggested that many new treatments
for hematologic malignancies, including MM, are also cost
effective [11]. The impact of transplantation on outcome
and its cost effectiveness need to be evaluated in the context
of the currently approved treatments. More efforts are
required to compare and clarify the cost effectiveness of
current available treatments to encourage cost-conscious
responsible choices that could improve heath outcomes
and save money.
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